Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

July 5, 2022 by Alan Khadavi

Itepekimab (Anti IL-33) & Brodalumab (Anti IL-25) for Asthma

Itepekimab and Brodalumab are two biologic medications being studied for asthma. Current biologics including Xolair, Nucala, Fasenra and Dupixent target downstream IgE, cytokines IL-5 and IL-4/13, have shown promising effects in terms of reduced asthma exacerbation rates, oral steroids, improved breathing capacity and asthma scores.

However approximately 30% of patients receiving biologics do not improve significantly. Instead of blocking downstream cytokines, targeting upstream alarmins, including IL-33, TSLP and IL-25, have been proposed to tackle the diverse causes of asthma.

We have discussed the above biologics in the past, here is a review of them below. We will discuss new ones on the horizon, Itepekimab and Brodalumab.

Asthma biologic agents (Xolair, Cinqair, Nucala, Fasenra, Dupixent)

Tezspire Tezepelumab for Severe Asthma

Itepekimab (Anti IL-33)

IL-33 is an inducer of Th2 adaptive immunity and signals via the IL-1 receptor-related protein ST2 triggering the release of chemokines and cytokines that promote T2 inflammation. Elevated levels of IL-33 mRNA produced by airway smooth muscle cells are detected from patients with asthma.

Itepekimab is an anti IL-33 monoclonal antibody, given subcutaneously 300mg every 2 weeks. Improvements in asthma control were statistically better than placebo.

Itepekimab in Asthma and COPD

Brodalumab (Anti IL-25)

IL-25 also known as IL-17E, is produced by bronchial epithelial cells and activates TH2 cells, basophils, eosinophils and mast cells, perpetuating T2 inflammation response in asthma. It has been shown IL-25 is associated with airway remodeling, which contributes to asthma severity.

In a phase 2 study, anti IL 17RA monoclonal antibody, brodalumab. Early studies did not show improvements in asthma control in patients with moderate to severe asthma. Further studies on the efficacy of anti-IL-25 blockade on other key outcomes will be needed.

Head to head biological asthma medications are unlikely in the near future. But picking the right one is crucially important by your asthma doctor. Blood eosinophil counts, total IgE and other comorbid conditions can help guide your doctor to pick the right one for you.

Filed Under: Asthma, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page